JS001: Clinical Trials

59 trials of JS001, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 unknown, 16 recruiting, 4 active not recruiting, 4 not yet recruiting. 59 Phase 2, 6 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 259Unknown 29, Recruiting 16, Active not recruiting 4, Not yet recruiting 4, Completed 2, Terminated 2, Withdrawn 2
Phase 16Unknown 4, Not yet recruiting 1, Terminated 1
Phase 33Unknown 2, Active not recruiting 1

Follow JS001: new trials by email Literature Review of JS001 trials Research Report on JS001

Trials (filtered) newest first · largest first

All 59 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
Toripalimab, Gemcitabine (GEM), Mitomycin C (MMC) - Urinary Bladder Neoplasms, Carcinoma, Transitional Cell
Phase 2Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical University1062026-12-012026-09-08
Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance Status
Toripalimab, Paclitaxel - Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Phase 2Not yet recruitingBarbara Ann Karmanos Cancer Institute222026-09-302026-08-31
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
Disitamab vedotin, Toripalimab, Sitagliptin - Bladder Urothelial Carcinoma, Bladder Cancer
Phase 2RecruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen University802026-07-012026-07-21
A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
JS212, JS001, 5-FU - Advanced Esophageal Squamous Cell Carcinoma
Phase 2RecruitingShanghai Junshi Bioscience Co., Ltd.2802026-04-132026-04-22
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
Probiotic, Disitamab Vedotin, Toripalimab - Muscle Invasive Bladder Cancer (MIBC)
Phase 2Not yet recruitingchenxu1462026-03-262026-03-17
PDT For Induction Therapy For Head And Neck Cancer
Toripalimab-tpzi, Cisplatin, Docetaxel - Squamous Cell Carcinoma, Head and Neck Cancer Squamous Cell Carcinoma
Phase 2RecruitingMassachusetts General Hospital262026-03-092026-10-19
FMD and Neoadjuvant Chemo-immunotherapy in TNBC
Fasting-mimicking diet, Chemotherapy, Toripalimab - Breast Cancer
Phase 2RecruitingSun Yat-sen University802026-03-052026-04-21
Toripalimab With Chemotherapy for Sinus Cancer
Toripalimab, Carboplatin, Docetaxel - Sinonasal Cancer, Paranasal Sinus Neoplasms
Phase 2RecruitingDana-Farber Cancer Institute202025-06-172026-08-31
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
Disitamab Vedotin, RC148, Albumin-bound Paclitaxone - Breast Cancer
Phase 2RecruitingRemeGen Co., Ltd.402025-02-102025-02-17
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
9MW2821, Toripalimab (JS001 ) - Urothelial Carcinoma, Urothelial Carcinoma Bladder
Phase 2RecruitingMabwell (Shanghai) Bioscience Co., Ltd.602025-01-172025-03-21
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
Disitamab Vedotin, Toripalimab - Breast Neoplasms
Phase 2WithdrawnRemeGen Co., Ltd.2024-12-202024-08-23
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
JS001, JS004, JS007 - Pancreatic Cancer
Phase 1 / Phase 2Not yet recruitingFudan University1172024-04-302024-04-17
To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Disitamab Vedotin for Injection, Toripalimab, Epirubicin - Breast Cancer
Phase 2RecruitingRemeGen Co., Ltd.792024-04-292024-05-23
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
Toripalimab, Gemcitabine, Cisplatin - Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor
Phase 2Active not recruitingSun Yat-sen University642023-12-012026-11-12
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Disitamab Vedotin Injection, Pertuzumab Injection, Toripalimab - Breast Cancer
Phase 2RecruitingRemeGen Co., Ltd.402023-11-282025-10-01
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Capecitabine, oxaliplatin, Disitamab Vedotin - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Phase 2RecruitingRemeGen Co., Ltd.902023-11-272023-12-14
Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma
Toripalimab, Anlotinib hydrochloride, Albumin paclitaxel - Esophageal Carcinoma, Neoadjuvant Therapy
Phase 2UnknownNanfang Hospital, Southern Medical University252023-09-012023-08-21
A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer
RC48-ADC(2.5mg/kg), Trastuzumab, Toripalimab - Gastric Cancer
Phase 2 / Phase 3Active not recruitingRemeGen Co., Ltd.2012023-08-042025-09-29
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
RC118, Toripalimab, RC148 - Advanced Solid Tumor
Phase 1 / Phase 2UnknownRemeGen Co., Ltd.482023-08-032025-01-29
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Disitamab Vedotin Injection (18 weeks), Toripalimab (18weeks), Carboplatin - Breast Cancer
Phase 2RecruitingRemeGen Co., Ltd.1202023-07-272024-03-19

Showing 20 of 59. Sign in to see all of them.

Conditions studied

Breast Neoplasms (7)  ·  Head and Neck Neoplasms (6)  ·  Stomach Neoplasms (6)  ·  Nasopharyngeal Carcinoma (5)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Squamous Cell Carcinoma of Head and Neck (4)  ·  Carcinoma, Transitional Cell (3)  ·  Colorectal Neoplasms (3)  ·  Nasopharyngeal Neoplasms (3)  ·  Urinary Bladder Neoplasms (3)  ·  Carcinoma, Squamous Cell (2)  ·  Esophageal Neoplasms (2)  ·  Carcinoma in Situ (1)  ·  Carcinoma, Neuroendocrine (1)  ·  Esophageal Squamous Cell Carcinoma (1)

Sponsors

RemeGen Co., Ltd. (9)  ·  Fudan University (8)  ·  Sun Yat-sen University (8)  ·  Peking University (2)  ·  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2)  ·  Taizhou Hospital (2)  ·  Tianjin Medical University Cancer Institute and Hospital (2)  ·  Ascentage Pharma Group Inc. (1)  ·  Barbara Ann Karmanos Cancer Institute (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  Dana-Farber Cancer Institute (1)  ·  First Affiliated Hospital of Guangxi Medical University (1)  ·  First Affiliated Hospital of Wenzhou Medical University (1)  ·  First People's Hospital of Foshan (1)  ·  Guangzhou Institute of Respiratory Disease (1)

Countries

China (52)  ·  United States (3)

Top investigators

Jianmin Fang, Ph.D (3)  ·  Lin Shen (2)  ·  Rui-hua Xu, PhD (2)  ·  Ammar Sukari, M.D. (1)  ·  Changling Li (1)  ·  Chao-su Hu, M.D. (1)  ·  Chaosu Hu, M.D. (1)  ·  Chong Zhao, M.D (1)  ·  Dingwei Ye, Doctor (1)  ·  Dongqing Lv, MD (1)  ·  Hongli Li, Dr (1)  ·  Juan Li, MD (1)  ·  Jun Guo, Ph.D (1)  ·  Jun Tang, MD (1)  ·  Kartik Sehgal, MD (1)

Results publications

PMID 19171491, PMID 23510863, PMID 25213161, PMID 25981818, PMID 26755520, PMID 30522017, PMID 30642373, PMID 34051177, PMID 34782428, PMID 37596191, PMID 38167937, PMID 38237373, PMID 38265030, PMID 38713205, PMID 38740030, PMID 38969879